Realizing Effectiveness Across Continents With Hydroxyurea (REACH)
Status:
Active, not recruiting
Trial end date:
2033-08-01
Target enrollment:
Participant gender:
Summary
REACH is a prospective, phase I/II open-label dose escalation trial of hydroxyurea for
children with confirmed SCA between 12 months and 10 years of age. The short-term goal is to
obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for
children with SCA in multiple distinct research settings in Africa. Based on that
information, the longer-term goal is to make hydroxyurea more widely available for children
with SCA in Africa, particularly those identified with SCA through expanded newborn screening
programs.